Dechra Pharmaceuticals PLC — AGM Information 2018

Oct 19, 2018

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 6478E

Dechra Pharmaceuticals PLC

19 October 2018

Date: 19 October 2018

Dechra® Pharmaceuticals PLC

Results of Annual General Meeting (AGM)

AGM Meeting Date: 10.30 am on 19 October 2018

Issued Share Capital at meeting date: 102,336,635

Number of shareholders in attendance: 9

All resolutions were passed on a show of hands.

Details of the proxy voting instructions lodged prior to the AGM are set out below:

Resolution (No. as noted on proxy form)	Total For (1)		Total Against		Withheld (2)
	No. of votes	% of vote	No. of votes	% of vote	No. of votes
Resolution 1: To receive the accounts, the Strategic Report, the Directors' Report and the Auditor's Report	73,623,740	95.88	3,162,913	4.12	377,261
Resolution 2: To approve the Directors' Remuneration Report	76,045,670	98.58	1,092,914	1.42	25,330
Resolution 3: To declare a final dividend	77,160,743	100.00	3,172	0.00	0
Resolution 4: To re-elect William Anthony Rice	71,931,907	93.24	5,212,000	6.76	20,007
Resolution 5: To re-elect Ian Page	76,265,790	98.84	898,039	1.16	86
Resolution 6: To re-elect Richard Cotton	76,089,363	98.61	1,074,466	1.39	86
Resolution 7: To re-elect Anthony Griffin	76,248,926	98.81	914,902	1.19	86
Resolution 8: To re-elect Julian Heslop	76,471,131	99.10	692,698	0.90	86
Resolution 9: To re-elect Ishbel Macpherson	76,540,810	99.22	603,098	0.78	20,007
Resolution 10: To re-elect Lawson Macartney	76,643,113	99.33	520,716	0.67	86
Resolution 11: To re-appoint PricewaterhouseCoopers as external auditor of the Company	76,021,787	98.52	1,141,654	1.48	473
Resolution 12: To authorise the Audit Committee to determine the remuneration of the external auditor	76,655,223	99.34	508,169	0.66	523
Resolution 13: To authorise the Directors to allot shares to specific limits	75,498,018	97.84	1,664,325	2.16	1,572
Resolution 14: To disapply the pre-emption rights	73,792,966	95.63	3,369,827	4.37	1,122
Resolution 15: To disapply additional pre-emption rights	73,637,601	95.43	3,523,885	4.57	2,428
Resolution 16: To authorise the Company to purchase its own shares	76,382,960	99.00	773,210	1.00	7,744
Resolution 17: To call general meetings (other than an AGM) on not less than 14 clear days' notice	75,446,021	97.77	1,717,894	2.23	0
Resolution 18: (a)  To approve the rules of the Dechra Global Save As You Earn Scheme 2018 (2018 SAYE Plan); and (b)  To authorise the Directors to adopt further plans based on the 2018 SAYE Plan	76,738,556	99.45	423,701	0.55	1,658

Notes

1.   Includes discretionary votes.

2.   A "vote withheld" is not a vote in law and is not counted in the calculation of the proportion of votes "For" and "Against" a resolution.

3.   Resolutions 1 to 13 and Resolution 18 were ordinary resolutions, requiring more than 50% of shareholder votes to be "For" the resolutions.

4.   Resolutions 14 to 17 were special resolutions, requiring more than 75% of shareholder votes to be "For" the resolutions.

5.   Votes tendered in respect of 77,163,915 shares representing 75.40% of the issued share capital.

In accordance with Listing Rule 9.6.2R, a copy of the resolutions passed as special business at the AGM have been submitted to the National Storage Mechanism and will shortly be available for inspection at www.morningstar.co.uk/uk/nsm.

For further information, please contact:

Melanie Hall, Company Secretary                           

Telephone number: 01606 814730

About Dechra

Dechra is an international specialist veterinary pharmaceuticals and related products business.  Our expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide. The majority of Dechra's products are focused on key therapeutic categories where we have leading market positions, and many of our products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products.  For more information, please visit: www.dechra.com.

Trademarks

Trademarks appear throughout this document in italics.  Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

RAGEAAENFDSPFFF